Xeris Biopharma Holdings Inc reports results for the quarter ended in March - Earnings Summary

Xeris Biopharma Holdings

09/05/2023 14:33

* Xeris Biopharma Holdings Inc  XERS.OQ  reported a
quarterly
adjusted loss of 12 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 17 cents per share.
    * Revenue rose 50.4% to $33.20 million from a year ago;
analysts
expected $30.77 million. 
    * Xeris Biopharma Holdings Inc's reported EPS for the
quarter was
a loss of 12 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Xeris Biopharma Holdings Inc shares had risen by 47.2%
this
quarter and gained 80.5% so far this year.
    * The company reported a quarterly loss of $16.83 million.
    * Wall Street's median 12-month price target for Xeris
Biopharma
Holdings Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.17          -0.12          Beat
 Dec. 31 2022      -0.16          -0.10          Beat
 Sep. 30 2022      -0.16          -0.16          Met
 Jun. 30 2022      -0.23          -0.19          Beat